flavoxate has been researched along with ephedrine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Applebaum, SM | 1 |
2 review(s) available for flavoxate and ephedrine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacologic agents in micturitional disorders.
Topics: Baclofen; Bethanechol Compounds; Dantrolene; Dicyclomine; Ephedrine; Flavoxate; Guanethidine; Humans; Imipramine; Mandelic Acids; Methyldopa; Neostigmine; Phenoxybenzamine; Phentolamine; Phenylephrine; Phenylpropanolamine; Propantheline; Propranolol; Quaternary Ammonium Compounds; Urinary Bladder; Urination Disorders | 1980 |
1 other study(ies) available for flavoxate and ephedrine
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |